for Chronic Hepatitis C (CHC) patients is the combination of pegylated interferon α 27 with ribavirin (2, 3) . Successful HCV treatment outcome, i.e. sustained virologic 28 response (SVR), is when a patient's viral load is below the HCV RNA detection limit at 29 a follow-up evaluation 24-weeks following treatment completion. SVR rates of up to 30 66% have been obtained with the optimal regimen of peginterferon α-2a plus ribavirin 31 in treatment-naïve patients in large, randomized, multicentre trials (4, 5) . Patients 32
infected with the more difficult to treat HCV genotype 1 (G1), which represent about 33 70% of CHC patients in the US (6) , are less likely to achieve an SVR than genotype 34 non-1 (Gn1) infected patients. Approximately 50% of HCV G1 infected patients 35 achieved an SVR when treated with peginterferon α-2a plus ribavirin, whereas 36 approximately 80% of HCV Gn1-infected patients achieved an SVR despite receiving a 37
shorter treatment duration and a lower ribavirin dose (5) . Thus, HCV patients represent 38 a population with continued unmet medical need, having the potential to achieve a 39 higher SVR rate through optimized treatment approaches. 40
Modeling hepatitis C virus (HCV) dynamics during therapy has led to important 41 insights into the life cycle of HCV elucidating the kinetic parameters governing viral 42 infection and hepatocyte death, the antiviral effects of interferons, and how ribavirin 43 impacts HCV treatment (7) . Models of HCV kinetics have provided a means to compare 44 different treatment regimens and outcomes in different patient populations (8) Inspection of the individual parameter estimates in patients experiencing a breakthrough 86 during therapy indeed showed that the administered drug therapy failed to decrease the 87 reproduction number (R T ) below 1 (17, 18) . The maximum hepatocyte proliferation rate 88 (r) was 0.00562 day -1 , and simulations based on this r revealed that the predicted liver 89 regeneration matched well with the increase in original liver volume in 51 donors as 90 measured 1 year after providing right-lobe liver grafts [Supplementary text note 3 91 online (19) ]. The typical value of the virion production rate p was 25.1 virions·day -1 and 92 the free virion clearance rate c was estimated to be 4.53 day -1 , corresponding to a free 93 virion half-life of 3.7 hours. This half-life lies within the previously reported range of 94 1.5-4.6 hours (12, 13) . Free virion clearance rate was found not to be influenced by HCV 95 genotype. In contrast, the infected cell death rate (δ) appeared to be dependent on HCV 96 genotype, and the typical value was estimated to be 0.139 day -1 in genotype-1 infected 97 patients and 0.192 day -1 in patients infected with HCV Gn1 (Table 1) . These estimates 98 are in line with previously reported values of δ (20) . The higher δ in HCV Gn1 infected 99 patients may indicate an enhanced immunological response and is in line with the 100 previous finding that a fast viral decay early in treatment correlates with SVR (20) . Also 101 the typical value of the PEG ED 50 was found to be lower in HCV Gn1 patients as 102 compared to patients infected with HCV G1, confirming the higher antiviral 103 effectiveness of peginterferon α-2a in blocking virion production in Gn1 patients 104
[ The multi-dimensional interactions between HCV virus, host and drug are highly non-136 linear and equilibrium outcomes quickly become counter-intuitive (24 (22) . 174
The implementation of the cure boundary in the viral kinetic model is physiologically 175 based and consistent with the primary goal of HCV therapy, which is to completely 176 eradicate the virus. The final viral kinetic model was implemented as a two state system. 177
The off state (null virion production) was triggered when there was less than one 178 
(1) 259 
where T ε is the total treatment-induced inhibition of the virion production. As infection 297 in the presence of an inhibitor has been shown to be cleared when R T < 1 (36), T ε 298 combined with R 0 are thus important predictors for a successful drug therapy. For this 299 reason, our model was parameterized in terms of R 0 , by using the following equation for 300
Finally, drug-effect after stopping treatment was described by an exponential decay 303 function ( The maximum number of hepatocytes present in an individual liver was assumed to be 313
2.50·10
11 hepatocytes (37). As HCV RNA is distributed in plasma and extracellular 314 fluids with a volume of approximately 13.5·10 3 mL (38), the maximum number of 315 hepatocytes (T max ) was assumed to be 18.5·10 6 cells·mL -1 (12) . Assuming a hepatocyte 316 turnover in a healthy liver of 300 days (39), the death rate of target cells (d) was set to 317 1/300 day -1 , and therefrom (T max ·d) the production of new hepatocytes in the absence of 318 liver disease (s) could be assumed to be 61.7·10 3 cells·mL -1 days -1 (12) . Estimated 319 proliferation rates were set to be equal across infected and uninfected hepatocytes due to 320 a lack of direct information to the contrary. 321
Non-linear mixed effects models comprise of a combination of fixed and random 322 effects. Individual parameters (PAR i ) in such a model are assumed to be log-normally 323 distributed and can be described by: 324 Our HCV viral kinetic model is able to describe all the typical phenomena observed after long-term therapy such as null response (no change in viral load), partial virologic response (initial decrease followed by increase during treatment), breakthrough during therapy (non-detectable viral load followed by increase during treatment), relapse after therapy (nondetectable viral load at the end of therapy followed by an increase during the treatment-free follow-up period), and SVR (non-detectable viral load at 24 weeks after end of therapy). 
Supplementary text note 2: basic reproduction number (R 0 )
The basic reproduction number of an infection is defined as the number of newly infected hepatocytes that arise from one infected cell when almost all cells are infected,
i.e. prior to treatment initiation (S1). When R 0 < 1, the infection will be spontaneously cleared in the long run. But if R 0 > 1, the infection will be able to expand. When R 0 = 1, the infection will not be cleared or expand but remain at some quasi-disease equilibrium. Using a simple PK-PD model for proliferative systems, it can be shown that the reproduction number in the presence of an inhibitor of the virion production (R T ) is (S2): ε is the total treatment-induced inhibition of the virion production. The infection in the presence of an inhibitor will die out in case R T < 1 (S2). R 0 thus carries information on the status of infection, whereas R T carries information about treatment effect and the likelihood of cure.
Simulations based on our HCV viral kinetic model confirmed the previous findings based on the simple PK-PD model for proliferative systems ( Figure S3) . The total drug effectiveness T ε combined with R 0 are thus important predictors for successful drug therapy. For this reason, our model was parameterized in terms of R 0 , by using the following equation for R 0 (S3):
In our model, the parameters d and s are assumed to be respectively 1/300 day -1 and 61.7·10 3 cells·mL -1 days -1 , whereas R 0 , c, p and δ are estimated so that the de novo infection rate constant β can be calculated.
Supplementary text note 3: liver proliferation rate (r)
The liver is a unique organ as it self-heals by regeneration as opposed to repair. The exact cellular and molecular mechanisms of liver regeneration are still not yet fully understood (S4,S5). The Neumann HCV viral kinetic model was extended with a density-dependent liver proliferation term to describe the liver regeneration (S6). For liver regeneration in healthy liver donors, the liver regrowth can be described in a similar way:
T represents the number of hepatocytes in cells·mL -1 . The maximum number of hepatocytes present in an individual liver (T max ) is assumed to be 18.5·10 6 cells·mL -1 . Table S1 ]. A total of 33 patients were found to be False Negative (observed SVR but model-predicted non-SVR), and 7 patients were found to be False Positive (observed non-SVR but model-predicted SVR). Based on these numbers, the sensitivity and specificity was calculated to be 96.6% and 99.4%, respectively. Although the difference in the number of correctly and incorrectly classified individuals is quite convincing, it should be noted that the sensitivity and specificity are positively biased as the rows and columns of Table S1 are not fully independent. The positive predictive value (PPV) and negative predictive value (NPV) was calculated to be 99.3% and 97.1%, respectively. In calculating these two statistics, it is assumed that the prevalence in the population at large is similar. 2 Specificity is calculated as 1,119 divided by 1,126 and expressed as %. 3 Positive predicted value (PPV) is calculated as 941 divided by 948 and expressed as %. 4 Negative predictive value (NPV) is calculated as 1,119 divided by 1,152 and expressed as %. 
